Clinical Trials Logo

Herpesviridae Infections clinical trials

View clinical trials related to Herpesviridae Infections.

Filter by:

NCT ID: NCT06401720 Enrolling by invitation - Clinical trials for SARS CoV 2 Infection

Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection

NPA-DC
Start date: January 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to understand immune responses to viral airway infection in adults, including the elderly. The main question(s) to answer is/are: Why do some individuals acquire only asymptomatic or mild Influenza A virus (IAV) infection while others become severely ill and even succumb to the same disease? Participants will be asked to donate samples when seeking health care for influenza-like symptoms or if hospitalized for IAV or SARS-CoV-2. Samples asked for are: - Blood sample by venepuncture - Blood sample by capillary sampling - Nasopharyngeal aspirate - Nasopharyngeal swab - Endotracheal tube aspirate - Nasal swab - Nasal curette - Breath Explor (sampling of expired air) Researchers will compare obtained results with the same type of samples from healthy controls.

NCT ID: NCT06384131 Not yet recruiting - Chronic Hepatitis B Clinical Trials

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection

Start date: April 30, 2024
Phase: Phase 1
Study type: Interventional

This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-4334 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis B e antigen (HBeAg) positive or negative. The study will enroll up to 5 sequential cohorts of 10 subjects each, for a total of up to 50 subjects, randomized 8:2 to receive ABI-4334 or placebo.

NCT ID: NCT06380647 Completed - Clinical trials for Herpes Virus Infection

Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns

childburn
Start date: October 1, 2019
Phase: N/A
Study type: Interventional

Introduction: Early detection is important in treating patients with Eczema Herpeticum (EH), which may arise in paediatric burn patients. As soon as a clinical diagnosis is confirmed, antiviral medications should be started to ensure an early resolution of the disease. Several studies have indicated that acyclovir is the best treatment for EH lesions in the majority of individuals. Objective: Compare efficacy of the prophylactic acyclovir and placebo in preventing eczema Herpeticum in paediatric burn patients

NCT ID: NCT06342921 Recruiting - Safety Issues Clinical Trials

ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection

ADC
Start date: December 7, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this Phase II/III study is to investigate the safty and efficacy of ADC189 tablets in adolescents and adults with influenza A virus infection/influenza B virus infection. The main aim to answer: - Phase II study is to evaluate the efficacy of ADC189 tablets in the treatment of adult influenza subjects and determine the optimal therapeutic dose by analyzing the time of virus titer turning to negative. All the results will be used to design the Phase III study. - Phase III study is to evaluate the efficacy of ADC189 tablets by analyzing the duration of remission of all influenza symptoms in adolescents and adults subjects with influenza. Participants will be taken ADC189 teblets/Placebo once, and be observed by 22 days. Phase II study has 3 groups: 15 mg ADC189; 45 mg ADC189; and Placebo; Phase III study has 2 groups: 45 mg ADC189; and Placebo.

NCT ID: NCT06311734 Active, not recruiting - Chronic Hepatitis B Clinical Trials

A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

Start date: November 1, 2021
Phase: Phase 1
Study type: Interventional

To Evaluate the Tolerability and Pharmacokinetics of LW231 Tablets in Single-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Single-dose, Multiple-dose Phase Ia Clinical Trials in Healthy Subjects .

NCT ID: NCT06236022 Recruiting - Clinical trials for Dilated Cardiomyopathy

The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

SDCMK
Start date: January 1, 2024
Phase: Phase 4
Study type: Interventional

Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.

NCT ID: NCT06159062 Not yet recruiting - Clinical trials for Chronic Hepatitis B Virus Infection

A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection

Start date: February 27, 2024
Phase: Phase 1
Study type: Interventional

The goal of this intervention research is to learn about the safety and tolerability of 162 with a single ascending dose in subjects with chronic hepatitis B virus (HBV) infection.

NCT ID: NCT06023056 Recruiting - Clinical trials for Blood Transfusion Complication

Hepatitis B Vaccination After Neonatal Surgery

Start date: November 1, 2022
Phase:
Study type: Observational [Patient Registry]

At present, whether the hepatitis B vaccine (HBV) can be vaccinated on time after neonatal surgery has become a common problem for children's families, neonatal surgeons, and vaccination departments, but there are few relevant studies at home and abroad, and there is no corresponding guide or consensus. In the early stage, our research team investigated the vaccination plans of the vaccination units in the main urban areas of Chongqing for such children through telephone follow-up, and found that the practices of each unit were different, all based on their own experience, and there was no clear evidence to support the vaccination or should not be vaccinated, which may cause some children to miss the best vaccination time or increase the risk of vaccination. The center is a relatively large neonatal surgery center in southwest China. The diagnosis and treatment of neonatal digestive tract malformations is at the leading level in China. It can carry out various neonatal operations such as neonatal necrotizing enterocolitis, congenital anorectal malformations, and congenital megacolon. On average, it carries out more than 30 third and fourth grade neonatal gastrointestinal operations every month. It has accumulated a lot of experience in the follow-up of newborns, There is a large amount of clinical data support for children who need to be vaccinated after surgery, so it is planned to follow up the second and third doses of hepatitis B vaccine and whether there are adverse reactions related to vaccination for children who need to be vaccinated after gastrointestinal surgery in the neonatal period, and at the same time check the production of HBsAb after vaccination, The immune response and adverse reactions of hepatitis B vaccine at different time points after surgery were studied to increase clinical evidence for the determination of hepatitis B vaccine vaccination program for newborns after surgery.

NCT ID: NCT05970289 Active, not recruiting - Clinical trials for Chronic Hepatitis B Virus Infection

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Start date: August 22, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.

NCT ID: NCT05897138 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses.